Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

  • ID: 3960466
  • Company Profile
  • 68 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amura Holdings Limited
  • F. Hoffmann-La Roche Ltd.
  • Fusion Antibodies Limited
  • Sanofi
  • Virobay Inc.
  • MORE
Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

The report ‘Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016’, provides an overview of the Taiho Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Taiho Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of Taiho Pharmaceutical Co., Ltd.
- The report provides overview of Taiho Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Taiho Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Taiho Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate Taiho Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Taiho Pharmaceutical Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Taiho Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amura Holdings Limited
  • F. Hoffmann-La Roche Ltd.
  • Fusion Antibodies Limited
  • Sanofi
  • Virobay Inc.
  • MORE
Introduction

Taiho Pharmaceutical Co., Ltd. Snapshot

Taiho Pharmaceutical Co., Ltd. Overview

Key Facts

Taiho Pharmaceutical Co., Ltd. - Research and Development Overview

Key Therapeutic Areas

Taiho Pharmaceutical Co., Ltd. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Taiho Pharmaceutical Co., Ltd. - Pipeline Products Glance

Taiho Pharmaceutical Co., Ltd. - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Taiho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Taiho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products

IND/CTA Filed Products/Combination Treatment Modalities

Preclinical Products/Combination Treatment Modalities

Taiho Pharmaceutical Co., Ltd. - Drug Profiles

(calcium folinate + gimeracil + oteracil + tegafur) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(gimeracil + oteracil + tegafur) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(tipiracil hydrochloride + trifluridine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bilastine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

netupitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-116 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-117 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-119 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-3681 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-5567 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trabectedin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Taiho Pharmaceutical Co., Ltd. - Pipeline Analysis

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Target

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action

Taiho Pharmaceutical Co., Ltd. - Dormant Projects

Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

(gimeracil + oteracil + tegafur)

(tipiracil hydrochloride + trifluridine)

orantinib

suplatast tosilate

Taiho Pharmaceutical Co., Ltd. - Company Statement

Taiho Pharmaceutical Co., Ltd. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

List of Tables

Taiho Pharmaceutical Co., Ltd., Key Facts

Taiho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016

Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016

Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016

Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016

Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016

Taiho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016

Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016

Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Taiho Pharmaceutical Co., Ltd. - Pre-Registration, 2016

Taiho Pharmaceutical Co., Ltd. - Phase III, 2016

Taiho Pharmaceutical Co., Ltd. - Phase II, 2016

Taiho Pharmaceutical Co., Ltd. - Phase I, 2016

Taiho Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016

Taiho Pharmaceutical Co., Ltd. - Preclinical, 2016

Taiho Pharmaceutical Co., Ltd. - Pipeline by Target, 2016

Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016

Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016

Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016

Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016

Taiho Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016

Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016

Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016

Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016

Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016

Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016

Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016

Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016

Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016

Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Amura Holdings Limited
- F. Hoffmann-La Roche Ltd.
- Fusion Antibodies Limited
- Sanofi
- Virobay Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll